the aid library

LIST OPTIONS

Filter

10831

Sort by:

Direction:

Download (108)

View PDF (136)

Strategy to Achieve Global Covid-19 Vaccination by mid-2022

World Health Organisation (WHO) (2021) C_WHO

Every country has been affected by COVID-19, with nearly a quarter of a billion cases and almost 5 million deaths reported globally as of end of September 2021. Despite the stunning speed with which highly effective and safe vaccines have been developed, new waves of disease are still pushin... more

Download (138)

View PDF (162)

Estimating COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalisations associated with laboratory-confirmed SARS-CoV-2

World Health Organization WHO (2021) C_WHO

Many critical questions remain about the effectiveness of COVID-19 vaccines in real-world settings. These questions can only be answered in post-introduction vaccine effectiveness studies.This guidance document outlines an approach to leverage existing surveillance systems for Severe Acute Respirato... more

Download (182)

View PDF (153)

AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine

World Health Organization WHO (2021) C_WHO

10 May 2021. Manufactureres: SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])] Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)] The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto... more

Download (162)

View PDF (221)

Защита здоровья человека посредством восстановления загрязненных участков

World Health Organization WHO, Regional Office of Europe (2021) C_WHO

This brief summarizes the lessons learned across Europe on the redevelopment of contaminated sites as a part of urban planning and renewal. Specifically, it aims to provide information on the health and environmental impacts to be considered during site redevelopment projects, and to identify good p... more

Download (103)

View PDF (144)

ChAdOx1-S [recombinant], COVID-19 vaccine

World Health Organization WHO (2021) C_WHO

Manufacturers: SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])] Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)] Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir... more

Download (942)

View PDF (1033)

WHO Guideline on Country Pharmaceutical Pricing Policies

World Health Organization WHO World Health Organization (2020) C_WHO

In recent years, high prices of pharmaceutical products have posed challenges in high- and low-income countries alike. In many instances, high prices of pharmaceutical products have led to significant financial hardship for individuals and negatively impacted on healthcare systems’ ability to prov... more

Download (87)

View PDF (152)

Containment strategies: lessons from early COVID-19 responses in five African countries

World Health Organization WHO, Regional Office of Africa; AHOP WHO Regional Office for Africa (2021) C_WHO

The number of COVID-19 cases is on the rise again, with South Africa nearing half of all confirmed cases in the WHO African Region. Threats of new variants loom and low vaccination coverage raises questions on the future of the response to COVID-19. Prevention remains the key strategy in most sub-Sa... more

Download (152)

View PDF (203)

Global initiative for childhood cancer

World Health Organization WHO (2020) C_WHO

Childhood cancer is curable for the vast majority of children when essential diagnostic, therapeutic and supportive care services are accessible. However, profound inequalities in outcomes exist within and between countries with as few as 20% or 30% of children living in low- and middle-income count... more

Download (126)

View PDF (165)

Addressing non communicable diseases in the COVID-19 response

World Health Organization WHO (2020) C_WHO

People with underlying noncommunicable diseases (NCDs) such as hypertension, diabetes, cardiovascular disease, chronic respiratory disease and cancer have a high risk for developing severe and even fatal COVID-19. It is important for them to strictly follow basic protective measures and make sure th... more

Download (72)

View PDF (117)

Gender and noncommunicable diseases in Ukraine: analysis of STEPS data

World Health Organization WHO, Regional Office of Europe (2020) C_WHO

This report is part of the gender and noncommunicable diseases (NCDs) initiative launched by the WHO Regional Office for Europe, which aims to strengthen the response to NCDs through a gender approach. It is part of a series of country profiles and a synthesis report. The country profile of Ukraine ... more

Download (407)

View PDF (354)

WHO report on cancer: setting priorities, investing wisely and providing care for all

World Health Organization WHO (2020) C1

Ramped-up cancer services could save 7 million lives over the next decade—and addressing huge service gaps between rich and poor countries is key to success, according to this report. In 2019, over 90% of high-income countries reported that comprehensive cancer treatment services were available... more

Download (114)

View PDF (155)

WHO recommends HIV self-testing – evidence update and considerations for success

World Health Organization WHO (2019) C_WHO

Policy brief. HIV self-testing (HIVST) is a convenient and confidential option for HIV testing. In 2016 WHO recommended HIVST as a safe, accurate and effective way to reach people who may not test otherwise, including people from key populations, men and young people. Lay users can perform HIVST r... more

Download (251)

View PDF (229)

Antimicrobial Resistance Background Document

National Department of Health South Africa (2019) C1

Antimicrobial resistance (AMR) is a multifaceted, international public health problem, which poses a direct threat to the safety of the population of South Africa. A national response is required to complement the development of a global plan, as articulated in the WHO’s draft resolution EB134/37 ... more

Download (198)

View PDF (186)

2019 Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline
recommended

World Health Organization WHO (2019) C_WHO

Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions. Gr... more

Download (131)

View PDF (167)

Commercial foods for infants and young children in the WHO European Region

World Health OrganizationEurope (2019) C_WHO

In order to help Member States understand what commercial foods for infants and young children are currently on the market, and to support implementation of the Guidance on ending inappropriate promotion of foods for infants and young children at the European level, the WHO Regional Office for Europ... more

Download (661)

View PDF (894)

Primary Eye Care training manual

World Health Organization WHO, Regional Office for Africa (2018) C_WHO

The purpose of this manual is to provide guidance in the design, implementation and evaluation of a course that aims to build and strengthen the capacity of health personnel to manage eye patients at primary-level health facilities in the African Region. The course falls within the remit of continuo... more

Download (123)

View PDF (130)

Expanding the Single-Visit Approach for Cervical Cancer Prevention: Successes and Lessons From Burkina Faso

Ouedraogo Y., Furlane G., Fruhauf T. et al. Global Health: Science and Practice (2018) CC

Background: Cervical cancer accounts for 23% of cancer incidence and 22% of cancer mortality among women in Burkina Faso. These proportions are more than 2 and 5 times higher than those of developed countries, respectively. Before 2010, cervical cancer prevention (CECAP) services in Burkina Faso wer...e limited to temporary screening campaigns. Program Description: Between September 2010 and August 2014, program implementers collaborated with the Ministry of Health and professional associations to implement a CECAP program focused on coupling visual inspection with acetic acid (VIA) for screening with same-day cryotherapy treatment for eligible women in 14 facilities. Women with larger lesions or lesions suspect for cancer were referred for loop electrosurgical excision procedure (LEEP). The program trained providers, raised awareness through demand generation activities, and strengthened monitoring capacity. Methods: Data on program activities, service provision, and programmatic lessons were analyzed. Three data collection tools, an individual client form, a client registry, and a monthly summary sheet, were used to track 3 key CECAP service indicators: number of women screened using VIA, proportion of women who screened VIA positive, and proportion of women screening VIA positive who received same-day cryotherapy. Results: Over 4 years, the program screened 13,999 women for cervical cancer using VIA; 8.9% screened positive; and 65.9% received cryotherapy in a single visit. The proportion receiving cryotherapy on the same day started at a high of 82% to 93% when services were provided free of charge, but dropped to 51% when a user fee of $10 was applied to cover the cost of supplies. After reducing the fee to $4 in November 2012, the proportion increased again to 78%. Implementation challenges included difficulties tracking referred patients, stock-outs of key supplies, difficulties with machine maintenance, and prohibitive user fees. Providers were trained to independently monitor services, identify gaps, and take corrective actions. Conclusions: Following dissemination of the results that demonstrated the acceptability and feasibility of the CECAP program, the Burkina Faso Ministry of Health included CECAP services in its minimum service delivery package in 2016. Essential components for such programs include provider training on VIA, cryotherapy, and LEEP; provider and patient demand generation; local equipment maintenance; consistent supply stocks; referral system for LEEP; non-prohibitive fees; and a monitoring data collection system. more

Download (609)

View PDF (1027)

WHO Expert Consultation on Rabies. 3rd report

Abela-Ridder, B. World Health Organisation (WHO) (2018) C_WHO

WHO TRS N°1012. Key updates include: (i) surveillance strategies, including cross-sectoral linking of systems and suitable diagnostics; (ii) the latest recommendations on human and animal immunization; (iii) palliative care in lowresource settings; (iv) risk assessment to guide management of bite... more

Download (461)

View PDF (425)

WHO recommendations: non-clinical interventions to reduce unnecessary caesarean sections

World Health Organization WHO (2018) C_WHO

This new guideline on non-clinical interventions to reduce unnecessary caesarean sections incorporates the views, fears and beliefs of both women and health professionals about caesarean sections. It also considers the complex dynamics and limitations of health systems and organizations and relation... more

Download (399)

View PDF (598)

Operational monitoring plan development: a guide to strengthening operational monitoring practices in small- to medium-sized water supplies

World Health Organization (WHO) (2017) CC

The guide is presented in two parts:
Part 1. Principles of Operational Monitoring: Describes the key principles of operational monitoring, alongside the types of operational monitoring that may be performed and the information required within an OMP.
Part 2. Operational Monitorin...g Plan Development: Describes the stepwise development of an OMP for a water supply system, including the source, water treatment, intermediate storage, distribution and household. For illustration purposes, practical guidance is provided using a specimen water supply system considered to be representative of a conventional small- to medium-sized supply in a lower resource setting. This template may be used to develop system-specific OMPs for individual water supply systems. more

2019 Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline recommended

2019 Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline
recommended